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Background: The emergence of novel coronavirus disease 2019 (COVID-19), caused by the Severe 
Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), has presented an  unprecedented 
global challenge for the healthcare community. The ability of SARS-CoV-2 to get  transmitted 
during the asymptomatic phase, and its high infectivity have led to the rapid transmission of 
COVID-19 beyond geographic regions facilitated by international travel, leading to a pandemic. 
To guide effective control and interventions, primary data is required urgently, globally,  including 
from low- and middle-income countries where documentation of cardiovascular manifestations 
and risk factors in people hospitalized with COVID-19 is limited.
Objectives: This study aims to describe the cardiovascular manifestations and cardiovascular 
risk factors in patients hospitalized with COVID-19.
Methods: We propose to conduct an observational cohort study involving 5000 patients 
recruited from hospitals in low-, middle- and high-income countries. Eligible adult COVID-19 
patients will be recruited from the participating hospitals and followed-up until 30 days post 
admission. The outcomes will be reported at discharge and includes the need of ICU admission, 
need of ventilator, death (with cause), major adverse cardiovascular events, neurological out-
comes, acute renal failure, and pulmonary outcomes.
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Conclusion: Given the enormous burden posed by COVID-19 and the associated severe prognos-
tic implication of CVD involvement, this study will provide useful insights on the risk factors 
for severe disease, clinical presentation, and outcomes of various cardiovascular manifestations 
in COVID-19 patients particularly from low and middle income countries from where the data 
remain scant.
Keywords: COVID-19; registry; cohort; survey; coronavirus; cardiovascular disease; rheumatic 
heart disease; chagas disease; HIV
Introduction
The coronavirus disease 2019 (COVID-19), was declared a pandemic by the World Health Organization 
(WHO) on March 11th 2020 [1]. Eight months later, COVID-19 has spread to more than 217 countries/areas/ 
or territories, affected over 105 million people and resulted in at least two million deaths (Figure 1), with 
substantially growing numbers of infections and deaths as the pandemic progresses in the low- and middle-
income countries (LMICs). Although 80% of all patients with confirmed COVID-19 may have only mild to 
moderate symptoms, the case-fatality ratio is highly variable depending on how the cases are defined, the 
testing practices, the health system access and other unknown factors. Reports provide a range between 
2–7% mortality overall and may be as high as 20% in the elderly [2]. Even within certain regions such as 
Africa the case-fatality rate due to COVID-19 ranged from 5.2% in Liberia to 8.6% in Chad [3].
The interaction between COVID-19 and the cardiovascular system has been a subject of special attention. 
The involvement of the cardiovascular system had already been described in other epidemics caused by 
corona viruses [6]. In COVID-19, patients with or at risk for cardiovascular disease (CVD) seem to be at greater 
risk of severe disease needing admission to an intensive care unit (ICU) and excess mortality [7, 8]. Also, 
there have been reports of cardiac complications in COVID-19 patients including myocardial injury, acute 
coronary events and heart failure. It has been reported that patients with these complications (including 
troponin elevation) are at a higher risk of mortality [9].
Most of the published data about the epidemiology and management of patients with COVID-19 infec-
tions are published from high-income countries. Figure 2 highlights that nearly 95% of the published 
original research papers are from the United States, Europe and Western Pacific region (mostly from China 
and Japan) whereas limited data are reported from other low- and lower middle-income regions e.g., Africa 
only form 0.4%.
Figure 1: Global Map of COVID-19 pandemic by region; adapted from World Heart Federation Briefing on 
Prevention: Coronavirus Disease 2019 (COVID-19) in Low-Income Countries [4] and Management of Cardio-
vascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings [5].
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However, over 90% of the poorest billion live in LMICs, and about 80% of them are younger than 40 years 
as highlighted in the recent The Lancet NCDI (non-communicable diseases and injuries) Poverty Commission 
report [10, 11]. Many CVDs such as rheumatic heart disease, congenital heart disease, peripartum and other 
cardiomyopathies, common contributors to CVD in LMICs lead to heart failure and premature death in 
young populations [12, 13]. It is currently unknown if patients in LMICs and LICs regions with cardiovascular 
diseases are vulnerable to COVID-19 leading to poor outcomes.
The management of more seriously ill patients with COVID-19 and CVD requires resources, like medi-
cal supplies, ventilators, personal protective equipment (PPE), that could become limited, even in high-
income countries. Understanding how countries where resources are scarce are dealing with the Pandemic 
is fundamental.
Rationale for the current study
As summarized above although there is emerging evidence that CVD, diabetes, and hypertension is asso-
ciated with COVID-19 and disease severity, SARS-CoV-2 itself may be cardiotropic in a subset of infected 
patients. Both acute and pre-existing CVD impact outcomes unfavourably. However, studies so far have, 
Figure 2: COVID-19 research output (in percentage) – Bibliometric analysis of the WHO COVID-19 research 
database.
Regions N Percentage
European Region 25,145 52.1
North America 19,271 39.9
Western Pacific Region 1,671 3.5
South-East Asia Region 882 1.8
South America 683 1.4
Eastern Mediterranean Region 432 0.9
African Region 187 0.4
Total 48,271 100.0
N = total number of original research publications.
Data source: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavi-
rus-2019-ncov.
* Search strategy run on 04 February 2021 with no restriction to language, publication year or journal/database. We only 
included original research studies related to risk factors, prognostic, diagnostic, aetiology, and observational studies, 
case report, screening study, prevalence, incidence, randomized trials, implementation research, qualitative research or 
health economic evaluations.
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perforce, been conducted with important limitations (e.g. small numbers, limited geographical representa-
tion, lack of data standardization for risk factors and outcomes, limited measurement, lack of appropriate 
adjustment for important confounders, not including CVD conditions common in LMICs, and missing 
data).
In order to reach robust conclusions that could inform clinical and policy practices, we initiated a global 
study for a better understanding of the cardiovascular conditions that increase the risk of developing severe 




•	 To describe cardiovascular outcomes among patients hospitalized with COVID-19; 




We will conduct a cohort study including consecutive confirmed COVID-19 patients in multiple countries.
Study setting: Participants will be recruited in any hospital where COVID19 patients are hospitalized. We 
have invited all WHF members from 100+ countries to identify three recruiting centres in their respective 





All adult (as locally defined) with confirmed PCR positive COVID-19 infection who are hospitalized are 
 eligible.
Exclusion criteria
Patients for whom we are unable to obtain informed consent will be excluded.
Patients who are unlikely to stay in the recruiting centre for 30 days (i.e. likely to be transferred) due to 
personal reasons or severe complications and unlikely to complete the 30-day follow-up visit.
Follow up
All patients will be followed up until 30 days, death or discharge whichever occurs first.  If patient is dis-
charged prior to 30 days, a phone contact will be made to find out whether patient is alive or dead (with 
cause) and if the patient had any re-hospitalization.
Table 1 reports the study measures included in this study and data collection source. In addition, each 
centre will provide the following information once at the beginning of the study: estimated size of popu-
lation served, total number of beds, number of ICU beds, number of ventilators, number of cardiologists, 
availability of echocardiogram (including point-of-care ultrasound), number of primary PCI cases/ ECMO/ 
heart transplantations performed per year prior to the COVID-19 outbreak.
Outcomes
The outcomes that we propose to measure include the need of ICU admission, need of ventilator, death 
(with cause), major adverse cardiovascular events (myocarditis, arrhythmia, heart failure [including 
LVEF], acute coronary event [type of MI]; neurological outcomes, acute renal failure, and pulmonary 
outcomes).
Data collection
This study will be coordinated from the Public Health Foundation of India (PHFI) and Centre for Chronic 
Disease Control (CCDC) (India) and conducted in hospitals in low-, middle- and high-income countries. Data 
will be collected at each site by local investigators and sent to the coordinating centre. Only data outlined 
on the entry (CRF Part 1) and outcome forms (CRF Part 2) will be collected. Each site will have a research 
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coordinator who will enter in-hospital entry and outcome form via a secure website throughout the entire 
study period. Hospital-level data will be collected just once when the hospital joins the study.
Study data will be collected and managed using the electronic data capture platform REDCap hosted at 
PHFI [14, 15]. REDCap is a secure, web-based software platform designed to support data capture for our 
study by providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manip-
ulation and export procedures; 3) automated export procedures for seamless data downloads to common 
statistical packages; 4) procedures for data integration and interoperability with external sources; and 5) safe 
and secure storage of all the audio files and study-related field-notes. The entry form will be used at hospital 
admission to collect baseline data. The outcome form will be completed 30 days after hospital admission or 
death or hospital discharge whichever occurs first. These data will be collected from the patient’s routine 
Table 1: Study measures and correlating data collection source for WHF Global study on COVID-19 and CVD.
Study Measure Details Data collection source
PART 1: ENTRY FORM
Demographics Age, sex, ethnicity, education, smoking status, pregnancy status eCRF & hospital records
COVID-19 symptom onset 
and admission vital signs
Symptom onset, admission date, temperature, oxygen, 
respiratory rate, blood pressure, height, weight, waist 
circumference, shortness of breath
eCRF & hospital records
Comorbidities 
( cardiovascular related 
prior to admission)
Coronary artery disease, stroke, peripheral vascular 
disease, atrial fibrillation, heart failure, cardiomyopathies, 
rheumatic heart disease, chagas disease, valvular disease, 
hypertension, diabetes
eCRF & hospital records
Comorbidities (non-cardiac 
related prior to admission)
Chronic pulmonary disease, asthma, tuberculosis, HIV, 
renal replacement therapy, chronic kidney disease
eCRF & hospital records
Cardiovascular medica-
tion (Pre-admission)
Beta-blockers, alpha blockers, diuretics, ACE-inhibitors, anti-
coagulants, anti-platelets, ARB, calcium antagonists, aldos-
terone antagonists, endocarditis prophylaxis, nitrates, statins
eCRF & hospital records
Non-cardiovascular medi-
cation (Pre-admission)
Anti-diabetic drugs, NSAIDS, allopurinol, anti-depressants, 
anti-retroviral therapy, influenza vaccine in the past 6 
months
eCRF & hospital records
Laboratory tests on 
admission
Complete blood count, liver function tests, kidney func-
tion tests, cardiac biomarkers (Troponin-T, I, NT proBNP, 
CK-MB), lipids
eCRF & Lab reports
Examinations ECG, ECHO, Chest-X-ray, CT-Scan
Anonymized ECG data will be uploaded to a web-based 
platform to be read and codified in a centralized reading 
centre by experienced and certified cardiologists.
eCRF & hospital records
Medications during 
 hospitalization
Intravenous fluids, antivirals, ACE-I, ARB, NSAIDS, antibiot-
ics, anti-malarial agent, anti-fungal agent, corticosteroids
eCRF & hospital records
Supportive care during 
hospitalization
ICU admission, oxygen therapy, non-invasive and invasive 
ventilation, inotropes, extracorporeal support
eCRF & hospital records
PART 2: OUTCOME FORM
At discharge Blood pressure, heart rate, time in ICU, cardiovascular 
events, acute respiratory distress syndrome, pneumonia, 
acute renal injury, liver dysfunction, death (cause of death)
eCRF & discharge 
 summary
30-day follow-up Vital stats (alive or death), re-hospitalization, recovery 
from COVID-19
Phone or clinic visit
Hospital and Provider 
level information
Hospital facilities (hospital beds, ICU, ventilators), avail-
ability of services (ECG, ECHO, x-ray, CT-scan, cardiac cath 
lab) human resources (cardiologists, pulmonologists, infec-
tious disease specialists)
Hospital records
ACEi = angiotensin-converting enzyme inhibitor, ARB = angiotensin II receptor blocker, ECG = electrocardiogram, ICU = 
intensive care unit, NSAIDS = non-steroidal anti-inflammatory drugs.
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medical records and no special tests will be required.  We will also collect data on ECG (scanned copies of 
ECG and/or digital files) and echocardiogram (raw DICOM) conducted as part of the usual clinical care of 
patients. ECG exams will be uploaded to a web-based platform to be read and codified in a centralized read-
ing centre, [16] according to the Minnesota Code, by experienced and certified cardiologists. Automatic 
measurements of ECG intervals, including the QT interval, will be reviewed. ECG (xml or image files) and 
echo images (raw DICOM) will be anonymized at sites via provided software and sent via encrypted cloud for 
central reading. All vetted researchers will be given free access to the online platform and machine learning 
tools to do further research.
Data management
Source Data
Data will be collected directly from the patient’s routine medical records, clinical notes at hospital admission, 
and at 30 days, discharge or death, whichever occurs first, using CRFs administered by study investigators. If 
a patient is discharged before 30 days investigators will make a phone contact to find out whether patient is 
alive or death at 30 days and if the patient had re-hospitalization. The CRF (source notes) will be completed 
in English for each enrolled patient. Study personnel and the principal investigator at each centre will be 
responsible for evaluating the CRFs for accuracy and completeness before entering into the online electronic 
clinical data management system. Once entered, the data manager will review the data for discrepancies and 
missing data. The site will then be informed to make any required corrections and/or additions and the CRF’s 
stored until all analyses are completed. The principal investigators and the study site research coordinator 
will be required to respond to the data queries and confirm and correct the data. A printed copy of the CRF 
and individual informed consents will be maintained in the participant’s file. Confidentiality of participant’s 
data will be maintained in accordance with national laws with the informed consent form containing a state-
ment describing the extent to which confidentiality of the participant will be maintained.
Database
Study personnel at the participating sites will be responsible for completing CRFs through remotely access-
ing a centralized electronic clinical data management system (Redcap). Appropriate training will be provided 
to the clinic site teams for entering data into the electronic data capture system by the project manager. 
PHFI/CCDC will be serving as the Research Coordinating Centre and will have access to all the study data. 
Individual sites will have access to their own centres’ data and will be provided site-specific data summaries 
by CCDC’s data management team, upon request.
Access to data, ownership, disclosure of data and publication
The Sponsor and coordinating centre (PHFI/CCDC) are responsible for storage, protection and retrieval of 
registry data. The Steering Committee is responsible for the guardianship and use of the data. PHFI/CCDC 
will have access to all the study data. Individual sites will have access to their own centres’ data. Each site 
personnel who is responsible for entering and reviewing participant data on the Electronic Clinical Data 
Management System will be provided access with a secure password. Sites will be provided with site-specific 
data summaries by PHFI/CCDC, upon request. All publications will be approved by the Steering Commit-
tee who will be named on all reports. The research teams, research nurses, collaborating doctors, and their 
respective units will be named, and study participants acknowledged in the final report and in publications 
arising from this registry. Acknowledgement in a future publication will be offered to all participating cen-
tres, national leaders, and site investigators that have provided valid data sets, according to the World Heart 
Federation Steering Committee.
Sample size and analysis
We will invite all WHF members (Scientific Societies and Foundations) from 100+ countries to take part 
in this study. Assuming that 35 members identified at least two hospital sites, recruiting an average of 75 
patients each, we will be able to recruit 5,200 participants. With this sample size, and assuming a prevalence 
of 8% for potential risk factor (hypertension), we will have the power to detect a RR of 2.0 for poor outcomes 
(myocarditis, and other major adverse cardiovascular events. We will also be able to estimate outcomes 
with 95% precision (confidence interval). A sample size of 5000 participants produces a two-sided 95% 
 confidence interval with a width equal to 0.008 when the sample proportion (prevalence of cardiovascular 
risk factors) is 0.08.
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Statistical analyses
Data will be reported as a number (proportion) of patients for categorical variables, mean (SD) for normally 
distributed continuous variables, and median (IQR) for skewed distributions. Data-derived and previously 
published multivariate models for in-hospital or post-discharge mortality and complications will be used to 
adjust for significant covariates.
Institutional Ethics Committee Approval
Institutional ethics approval for the project has been obtained from the University of Cape Town, South 
Africa and the coordinating centres in India (PHFI and CCDC). In addition, all investigators will obtain ethi-
cal approval from their institutional ethics committees prior to patient recruitment in the study. Eligible 
patients will be approached regarding potential participation in the study and the study purpose, risks, 
and potential benefits will be explained by the study coordinator and/or principal investigators. Potential 
patients will be given the opportunity to ask questions. Patients who voluntarily agree to participate in the 
study will be asked to document their informed consent.
Informed Consent
The investigator or the person designated by the investigator should fully inform the patient of all the 
important aspects of this observational study, including the approval by the ethics committee of the study 
protocol. Informed consent should be guided by local ethical requirement and in some institutions can be 
verbal. Prior to the participation of the patient in the study, the informed consent form should be signed and 
personally dated by either the patient or the patient’s legally acceptable representative, and by the person 
who conducted the informed consent interview. For those patients who are directly unable to provide writ-
ten informed consent (due to admitted in ICU or unconscious), consent could be obtained from a legally 
acceptable representative and/or in the presence of an impartial witness if acceptable by local regulation. 
Informed consent process will be guided by the local ethics and regulatory requirements as applicable for 
the COVID-19 research projects.
Participant’s confidentiality
Study data sent to the Electronic Data Management System at the Research Coordinating Centre at CCDC 
will be securely stored. Source documents pertaining to the study which is maintained in each partici-
pating site will be stored securely by the site coordinator, in accordance with the ethical requirements. 
Informed consent will be obtained from the participants to collect, transmit and store identifiable personal 
information.
Identifiable data collected during this study will be replaced by a code number. This number will be used 
for study documentation, in reports or publications. The study data once analysed and published will be 
stored for a maximum of 15 years.
Study Management and governance
Principal Investigators
Dorairaj Prabhakaran, Karen Sliwa, Pablo Perel.
Co-investigators
Fausto Pinto, Dike Ojjii, Carolyn Lam, Friedrich Thienemann, Junbo Ge, Amitava Banerjee, Kristin Newby, 
Antonio Luiz Ribeiro, Samuel Gidding.
National Leaders and site investigators will constitute the larger team contributing to this cohort 
study and will be acknowledged to future publications as per the ESC and EOPR publications and author-
ship policy.
Study Steering committee
The Steering Committee will be the decision-making body of this registry. It will consist of members of PHFI 
and CCDC, India (DP, KS), LSHTM, UK (PP) and University of Cape Town, South Africa (KS) will meet, via tel-
ephone conference, on approximately a weekly basis (or less frequently if deemed appropriate) to address the 
operational and scientific matters of the study. The Steering Committee will make the major decisions regard-
ing the project, including: the scientific direction of the project, including partner responsibilities and any 
changes in budgetary allocations, the dissemination and exploitation strategy; and any administrative and 
legal decisions relating to the registry’s contractual obligations to the study sponsor (World Heart Federation).
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The daily administrative, scientific and technical management of the project will be executed by a Project 
Management Team based at PHFI/CCDC, consisting of the Principal Investigator (DP), co-investigator (KS) 
and the Project Manager. The Project team will have support by the World Heart Federation. The Project 
Management Team will help carry out the decisions of the Steering Committee and will be supported in its 
tasks by the administrative resources based at PHFI/CCDC.
Study implications
This global cohort study will provide insights into the cardiovascular outcomes and cardiovascular risk fac-
tors among hospitalized patients with confirmed COVID-19. In addition, this study will highlight the eth-
nic difference and health system differences in poor cardiovascular outcomes in hospitalized patients with 
COVID19. By providing comparable data from countries around the globe, the study will inform the delivery 
of care for patients with COVID-19, with underlying cardiovascular conditions or with cardiovascular com-
plications as well as will contribute to potential meta-analysis with data from other global registries focused 
on COVID-19 and CVD outcomes. This study has additional implications. Recent data from UK shows eth-
nic differences in the need for hospitalization and differences in the incidence of death. For example, a 
study showed black patients had a higher odds of hospitalisation but similar death rates compared to white 
patients while South Asians had higher odds of death once hospitalized but similar rates of hospitalisation 
as compared to whites [17]. These findings were observed in an advanced health system. Our study has the 
potential to compare both ethnic differences as well as health system variations and also contribute to meta-
analysis from multiple studies.
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